Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the United States Food and Drug Administration (FDA) has granted…

Continue Reading Oncternal Therapeutics Announces Orphan Drug Designations of Cirmtuzumab ROR1 Antibody for Treatment of Mantle Cell Lymphoma and for Treatment of Chronic Lymphocytic Leukemia
FDA Approves CRYSVITA for Tumor-Induced Osteomalacia
source: pixabay.com

FDA Approves CRYSVITA for Tumor-Induced Osteomalacia

Ultragenyx Pharmaceutical's therapy, CRYSVITA, has recently been approved by the FDA for the treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors. This approval comes after…

Continue Reading FDA Approves CRYSVITA for Tumor-Induced Osteomalacia
International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers
source: pixabay.com

International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers

  COVID-19 has now taken hold in over one hundred eighty countries. According to a recent article in The Lancet, in May of 2020, the United States reported the highest…

Continue Reading International Panel Gives Expert Advice on the Management of COVID-19 and Blood Cancers
Early Success in Trials for Experimental Gene Therapies for Fabry Disease and Cystinosis
source: pixabay.com

Early Success in Trials for Experimental Gene Therapies for Fabry Disease and Cystinosis

As reported in Business Fortnight, the top level gene therapy company AVROBIO has announced successful clinical trials for investigational drugs for Fabry disease and cystinosis. The CEO of AVROBIO, Geoff…

Continue Reading Early Success in Trials for Experimental Gene Therapies for Fabry Disease and Cystinosis
An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation
source: pixabay.com

An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation

According to a story from BioSpace, the biopharmaceutical company Dicerna Therapeutics, Inc. has announced recently that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to…

Continue Reading An Experimental Treatment for Primary Hyperoxaluria has Earned Rare Pediatric Disease Designation
Dr. Eunice Wang Discusses Newly Approved Treatments for Acute Myeloid Leukemia
source: pixabay.com

Dr. Eunice Wang Discusses Newly Approved Treatments for Acute Myeloid Leukemia

  Earlier this year, The Leukemia & Lymphoma Society hosted a presentation by Dr. Eunice Wang, Clinical Leukemia Service, Professor of Oncology, Roswell Park Comprehensive Cancer Center. Dr. Wang’s presentation…

Continue Reading Dr. Eunice Wang Discusses Newly Approved Treatments for Acute Myeloid Leukemia
New Treatment Approved in Canada for Gastrointestinal Stromal Tumor
source: pixabay.com

New Treatment Approved in Canada for Gastrointestinal Stromal Tumor

According to a story from Biotech 365, the biopharmaceutical company Deciphera Pharmaceuticals has recently announced that the company's drug ripretinib (marketed as QINLOCK™) has been approved by Health Canada. The…

Continue Reading New Treatment Approved in Canada for Gastrointestinal Stromal Tumor

Perturbations in the Body’s Internal Clock Linked to Greater Risk of Parkinson’s, Study Finds

Older men who have a weak or irregular circadian rhythm — the body’s internal clock that controls the sleep-wake cycle — are approximately three-times more likely to develop Parkinson’s disease…

Continue Reading Perturbations in the Body’s Internal Clock Linked to Greater Risk of Parkinson’s, Study Finds
New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated
source: pixabay.com

New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated

Antigen-specific T-cell therapy is an innovative treatment option which uses immune cells to combat cancer cells. AdventHealth is the very first in the world to use this treatment for patients…

Continue Reading New Investigative Therapy for Acute Myeloid Leukemia and Myelodysplastic Syndromes is Being Investigated

Regeneron Pharmaceuticals is Racing to Have an Antibody “Cocktail” Against COVID-19

Regeneron Pharmaceuticals recently announced that it is testing a medicine for the treatment and/or prevention of Covid-19. According to an article by CNN, the testing of its anti-SARS-CoV-2 antibody combination…

Continue Reading Regeneron Pharmaceuticals is Racing to Have an Antibody “Cocktail” Against COVID-19